We searched PubMed for articles published between Jan 1, 1969, and Jan 21, 2016, with the search terms “Down OR Downs OR Down's”, “syndrome”, “dementia”, “cognitive”, and “Alzheimer OR Alzheimer's”. Additional search terms were used for specific sections of the Review: “prevalence”, “incidence”, “epidemiology”, “frequency”, “diagnosis”, “assessment”, “identification”, “neuroimaging”, “biomarker”, “pathology”, “neuropathology”, “genetic”, “gene”, “genotype”, “GWAS”, “transgenic”,
ReviewDementia in Down's syndrome
Introduction
Down's syndrome affects 5·8 million people worldwide and is the most common genetic cause of learning difficulties.1 The incidence of age-related cognitive decline and dementia is higher in individuals with the syndrome than in the general population, and progressive cognitive impairment develops at a far earlier age: the median age of dementia onset across all reported studies is below 60 years (table 1),2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and Down's syndrome dementia is the most common form of dementia in individuals under the age of 50 years.1 Dementia in Down's syndrome presents a major diagnostic and clinical management challenge because of the combination of learning disabilities, progressive cognitive and functional decline, and associated neuropsychiatric and behavioural symptoms. Incidence of Down's syndrome has decreased by 1% in the UK since the introduction of antenatal screening in the early 1990s, although an increase in birth rates of babies with Down's syndrome has been reported in the USA as a result of older maternal age.18 With more people living beyond age 60 years,19 dementia in Down's syndrome is likely to be an increasing challenge.
In the past decade, substantial progress has been made in the search for genetic risk factors for dementia in people with Down's syndrome, and in understanding the neuropathological similarities and differences between Down's syndrome dementia and Alzheimer's disease without Down's syndrome. In turn, this progress has led to opportunities in drug development, including the use of transcriptional analysis to identify treatment targets, and the emergence of potential new targets based on knowledge of neurogenesis pathways and genes such as DYRK1A.20 Additionally, studies of new potential therapies are underway, such as the use of vitamin E to target oxidative stress (NCT01594346), and repurposing of existing therapies is a valuable opportunity for treatment development.
In this Review, we summarise published work on progressive dementia in people with Down's syndrome and explore potential avenues for future research. We first briefly describe the epidemiological and clinical characteristics of dementia in Down's syndrome, and then focus on the most recent developments in the neurobiology of dementia in this population, including imaging and pathophysiological changes and genetic risk factors. Additionally, we discuss existing treatment strategies and the most innovative and promising opportunities for drug development in the context of emerging knowledge from neuropathological and genetic research. A developmental approach that considers the effect on neuronal development, prodromal pathologies, and symptoms in young people with Down's syndrome is also an important area, although the focus of this Review is on the progressive cognitive impairment that is associated with Alzheimer's disease in people with Down's syndrome older than 40 years.
Section snippets
Epidemiology
Results from cross-sectional and longitudinal studies2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 show a wide range in prevalence, and substantial variability in the age of onset, of clinically significant cognitive impairment and dementia in people with Down's syndrome across all age groups (table 1). A clear age-related trend exists for emergence of impairment.4, 5, 6, 7, 9, 10, 11, 12, 13, 15, 16, 17 Results from eight studies4, 6, 7, 9, 10, 13, 15, 17 show rising prevalence from
Clinical presentation and assessment
For people older than 40 years with Down's syndrome, dementia development follows a similar course to that seen in Alzheimer's disease,6, 8 with declines in recall and explicit memory21 and in receptive language function22 usually preceding dementia. However, when dementia emerges in younger individuals (aged 30–40 years), it often initially manifests as changes in behaviour and personality,6, 8 including onset of apathy, increasing impulsivity, and executive dysfunction.
Of note, some reports
Imaging findings
Perhaps the most striking parallels between Alzheimer's disease and Alzheimer's disease in Down's syndrome are common neuropathologies, including the characteristic accumulation of amyloid-β (Aβ).28 In MRI and PET studies of people with Down's syndrome, changes in hippocampal volume, glucose metabolism, and amyloid burden have been identified across a large age range. For example, in a study of individuals (aged 34–52 years) with Down's syndrome but not dementia,29 reduced grey matter volume on
Genetic risk factors
The wide variation in age of dementia onset in individuals with Down's syndrome suggests that substantial differences exist between alleles of key genes for Alzheimer's disease on chromosome 21, or in other genes that regulate dementia risk, or both. Understanding these differences could be the key to the identification of new approaches to delay and treat Alzheimer's disease in people with Down's syndrome.
Existing treatments for Alzheimer's disease
The UK National Institute for Health and Care Excellence recommends treatment with cholinesterase inhibitors and the NMDA receptor antagonist memantine for people with moderate to severe Alzheimer's disease and their use is also approved in the context of learning disability. The US guidelines for treatment of people with learning disabilities are more nuanced and recommend decisions based on individual patient assessments.119, 120 Although evidence from preclinical models suggests that
Conclusions
In this Review, we have focused on new findings in the genetic and neuropathological manifestations of Down's syndrome, and examined how this knowledge might be applied to the development and design of treatments. We are in an encouraging, but preliminary, position in this regard. A large RCT of vitamin E is still in progress, but other clinical trials are preliminary. Results from studies in mouse models of Down's syndrome suggest that some targets of Alzheimer's disease might be of particular
Search strategy and selection criteria
References (152)
- et al.
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial
Lancet
(2012) Down syndrome, Alzheimer's disease and seizures
Brain Dev
(2005)- et al.
An experimental approach to detecting dementia in Down syndrome: a paradigm for Alzheimer's disease
Brain Cogn
(2007) - et al.
Some morphometric observations on the brains of patients with Down's syndrome: their relationship to age and dementia
J Neurol Sci
(1990) - et al.
Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events
NeuroImage
(2008) - et al.
Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia
Alzheimers Dement
(2015) - et al.
Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B
Alzheimers Dement
(2012) - et al.
The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome
J Neurol Sci
(1989) - et al.
Biomarker modeling of Alzheimer's disease
Neuron
(2013) - et al.
Plasma beta amyloid and the risk of Alzheimer's disease in Down syndrome
Neurobiol Aging
(2012)
Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation
Neurobiol Dis
Alzheimer's disease
Lancet
Characteristic developmental expression of amyloid beta40, 42 and 43 in patients with Down syndrome
Brain Dev
Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations
Am J Pathol
Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance
J Biol Chem
Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome
Exp Neurol
Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome
Exp Neurol
Expression of APP pathway mRNAs and proteins in Alzheimer's disease
Brain Res
Positive and negative regulation of APP amyloidogenesis by sumoylation
Proc Natl Acad Sci USA
Sorting nexin 27 regulates Abeta production through modulating gamma-secretase activity
Cell Rep
Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome
Neurobiol Aging
Lack of association between the polymorphisms of beta-site APP-cleaving enzyme 2 (BACE2) 5'-flanking region and sporadic Alzheimer's disease
Brain Res
Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells
J Biol Chem
DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects
Neurobiol Dis
Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies
Neurosci Lett
Dynamin is a minibrain kinase/dual specificity Yak1-related kinase 1A substrate
J Biol Chem
Molecular mechanisms of cellular cholesterol efflux
J Biol Chem
Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation
J Biol Chem
New insights into the therapeutic potential of Girk channels
Trends Neurosci
Demographic characteristics, health conditions, and residential service use in adults with Down syndrome in 25 U.S. states
Intellect Dev Disabil
Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology
J Intellect Disabil Res
Dementia and mortality in persons with Down's syndrome
J Intellect Disabil Res
Dementia in people with Down's syndrome
Int J Geriatr Psychiatry
Incidence and course of dementia in people with Down's syndrome: findings from a population-based study
J Intellect Disabil Res
Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome
Br J Psychiatry
A four year prospective study of age-related cognitive change in adults with Down's syndrome
Psychol Med
Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome
Eur Neurol
Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome
Am J Ment Retard
Normal ageing in adults with Down's syndrome: a longitudinal study
J Intellect Disabil Res
Prevalence of dementia in adults with and without Down syndrome
Am J Ment Retard
Age-specific prevalence, thyroid dysfunction and depressive symptomatology in adults with Down syndrome and dementia
Int J Geriatr Psychiatry
Cognitive impairment in adults with Down's syndrome: similarities to early cognitive changes in Alzheimer's disease
Neurology
Prevalence of dementia in adult patients with trisomy 21
Am J Med Genet Suppl
The natural history of dementia in Down's syndrome
Arch Neurol
A prospective study of Alzheimer disease in Down syndrome
Arch Neurol
Atypical aging in Down syndrome
Dev Disabil Res Rev
Cognitive decline in Down syndrome
Arch Neurol
A pilot study examining associations between DYRK1A and alpha-synuclein dementias
Neurodegener Dis
Effects of increasing task load on memory impairment in adults with Down syndrome
Am J Ment Retard
A five-year follow up study of adaptive behaviour in adults with Down syndrome
J Int Dev Dis
Cited by (165)
Creatine as a Therapeutic Target in Alzheimer's Disease
2023, Current Developments in NutritionUntangle the mystery behind DS-associated AD – Is APP the main protagonist?
2023, Ageing Research ReviewsPrediction of clinical progression in nervous system diseases: plasma glial fibrillary acidic protein (GFAP)
2024, European Journal of Medical ResearchCognitive reserve proxies for individuals with intellectual developmental disability: A scoping review
2024, Journal of Applied Research in Intellectual Disabilities